LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 97.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 97.00%, a 3.19% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 94.00%, a 2.08% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 96.00%, a 2.13% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 94.00%, a 4.44% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 94.00%, a 1.05% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 95.00%, a 1.06% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 94.00%, a 5.62% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 89.00%, a 2.20% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 97.00% 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 97.00% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 94.00% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 94.00% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 94.00% 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 94.00% 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | 95.00% 10-K · filed 2025-03-24 | |||
| 2024-09-30 | 96.00% 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | 96.00% 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | 96.00% 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 94.00% 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 94.00% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 94.00% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 94.00% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 89.00% 10-K · filed 2024-03-14 | |||
| 2022-09-30 | 89.00% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 89.00% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 90.00% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 91.00% 10-K · filed 2023-03-14 | |||
| 2021-09-30 | 91.00% 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 91.00% 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 91.00% 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | 91.00% 10-K · filed 2022-03-25 | |||
| 2020-09-30 | 91.00% 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 90.00% 10-Q · filed 2020-08-14 | |||
| 2019-12-31 | 77.00% 10-K · filed 2021-03-04 | |||
| 2019-09-30 | 77.00% 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 77.00% 10-Q · filed 2020-08-14 | |||
| 2016-12-31 | 87.00% 10-K · filed 2017-03-10 | |||
| 2015-12-31 | 87.00% 10-K · filed 2017-03-10 | |||
| 2014-12-31 | 90.00% 10-K · filed 2017-03-10 | |||
| 2013-12-31 | 85.00% 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |